Mohammad A Rahman1, Thomas M Keck1, Michael M Poe2, Dishary Sharmin2, James M Cook2, Bradford D Fischer3. 1. Department of Chemistry & Biochemistry, Department of Molecular & Cellular Biosciences, Rowan University, Glassboro, NJ, 08028, USA. 2. Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53201, USA. 3. Department of Biomedical Sciences Camden, Cooper Medical School of Rowan University, Camden, NJ, 08103, USA. fischerb@rowan.edu.
Abstract
RATIONALE: Opioid and GABAA receptors are both located in central nociceptive pathways, and compounds that activate these receptors have pain-relieving properties. To date, the interactive effects of concurrent administration of these compounds in preclinical models of pain-like behaviors have not been assessed. OBJECTIVE: The purpose of this study was to examine the interactive effects of the μ-opioid agonist morphine and the α2GABAA and α3GABAA receptor positive allosteric modulator methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024) in preclinical models of mechanical hyperalgesia and thermal nociception. METHODS: The antihyperalgesic and antinociceptive effects of morphine and MP-III-024 administered alone were assessed initially, followed by fixed-ratio mixtures of MP-III-024/morphine combinations. Drug interaction data were analyzed using isobolographic and dose-addition analyses. All studies were conducted in male CD-1 mice. RESULTS: In the assay of mechanical hyperalgesia, each compound produced dose-dependent antihyperalgesic effects, whereas only morphine was effective on thermal nociception. Fixed-ratio mixtures of MP-III-024/morphine were also dose-dependently effective in both procedures. These drug combination studies revealed that morphine and MP-III-024 produced supra-additive (synergistic) effects in both assays, depending on their relative proportions. CONCLUSIONS: These results demonstrate an interaction between α2GABAA and α3GABAA receptor- and μ-opioid receptor-mediated signals and suggest that combination therapy may be useful for the treatment of pain-related disorders.
RATIONALE: Opioid and GABAA receptors are both located in central nociceptive pathways, and compounds that activate these receptors have pain-relieving properties. To date, the interactive effects of concurrent administration of these compounds in preclinical models of pain-like behaviors have not been assessed. OBJECTIVE: The purpose of this study was to examine the interactive effects of the μ-opioid agonist morphine and the α2GABAA and α3GABAA receptor positive allosteric modulator methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024) in preclinical models of mechanical hyperalgesia and thermal nociception. METHODS: The antihyperalgesic and antinociceptive effects of morphine and MP-III-024 administered alone were assessed initially, followed by fixed-ratio mixtures of MP-III-024/morphine combinations. Drug interaction data were analyzed using isobolographic and dose-addition analyses. All studies were conducted in male CD-1 mice. RESULTS: In the assay of mechanical hyperalgesia, each compound produced dose-dependent antihyperalgesic effects, whereas only morphine was effective on thermal nociception. Fixed-ratio mixtures of MP-III-024/morphine were also dose-dependently effective in both procedures. These drug combination studies revealed that morphine and MP-III-024 produced supra-additive (synergistic) effects in both assays, depending on their relative proportions. CONCLUSIONS: These results demonstrate an interaction between α2GABAA and α3GABAA receptor- and μ-opioid receptor-mediated signals and suggest that combination therapy may be useful for the treatment of pain-related disorders.
Authors: Bradford D Fischer; Raymond J Schlitt; Bryan Z Hamade; Sabah Rehman; Margot Ernst; Michael M Poe; Guanguan Li; Revathi Kodali; Leggy A Arnold; James M Cook Journal: Brain Res Bull Date: 2017-03-04 Impact factor: 4.077
Authors: Bradford D Fischer; John R Atack; Donna M Platt; David S Reynolds; Gerard R Dawson; James K Rowlett Journal: Psychopharmacology (Berl) Date: 2010-12-30 Impact factor: 4.530
Authors: A Garcia de Lucas; P K Ahring; J S Larsen; I Rivera-Arconada; J A Lopez-Garcia; N R Mirza; G Munro Journal: Biochem Pharmacol Date: 2014-12-25 Impact factor: 5.858
Authors: Jolly Paul; Gonzalo E Yévenes; Dietmar Benke; Alessandra Di Lio; William T Ralvenius; Robert Witschi; Louis Scheurer; James M Cook; Uwe Rudolph; Jean-Marc Fritschy; Hanns Ulrich Zeilhofer Journal: Neuropsychopharmacology Date: 2013-08-28 Impact factor: 7.853